Drugs / SHR-1707
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06114745 | Apr 2024 → Jul 2025 | Alzheimer disease | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05681819 | Feb 2023 → May 2024 | Alzheimer disease | Shanghai Hengrui Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04973189 | May 2021 → Jan 2022 | Alzheimer disease | Shanghai Hengrui Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04745104 | Feb 2021 → Mar 2022 | Alzheimer disease | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06199037 | Feb 2024 → Jan 2026 | Alzheimer disease | Shanghai Hengrui Pharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-1707 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05681819 ↗ |
| Action | Inhibit | “SHR-1707 is a novel humanized anti-Aβ IgG1 monoclonal antibody that binds to Aβ fibrils and monomers to block the formation of Aβ plaques” PMID 39390616 ↗ Oct 2024 |
| Modality | Monoclonal antibody | “SHR-1707 is a novel humanized anti-Aβ IgG1 monoclonal antibody” PMID 39390616 ↗ Oct 2024 |
| Route | Intravenous | “SHR-1707 will be administered through IV infusion” NCT04745104 ↗ |